Nureca promoter Saurabh Goyal acquires 32.19 lakh shares

1 min read Updated on 04 Jul 2026, 12:43 AM

Reviewed by

Naman SScanX News Team

AI Summary

Promoter Saurabh Goyal acquired 32,19,113 equity shares of Nureca Limited through an off-market inter se transfer on July 2, 2026, under a Family Settlement Agreement. This increased his total shareholding to 64,97,169 equity shares, or 68.09% of the paid-up capital. The company disclosed the transaction to exchanges on July 3, 2026, under SEBI PIT Regulations.

*this image is generated using AI for illustrative purposes only.

Promoter Saurabh Goyal acquired 32,19,113 equity shares of Nureca Limited through an off-market inter se transfer on July 2, 2026. The transaction was executed under a Family Settlement Agreement dated June 17, 2026. Following this acquisition, Saurabh Goyal's total shareholding increased to 64,97,169 equity shares, representing 68.09% of the company's paid-up share capital. The company disclosed the details to the exchanges on July 3, 2026, pursuant to Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, as a precautionary measure despite specific SEBI circulars not mandating it.

The transfer was classified as an inter se transfer by way of gift. Prior to the transaction, Saurabh Goyal held 32,78,056 equity shares, accounting for 34.35% of the paid-up share capital. The acquisition significantly bolstered his stake in the company.

The following table details the changes in shareholding for the promoter:

S.No.	Particulars	Saurabh Goyal
1	Category	Director / Promoter
2	Pre-transaction holding	32,78,056 shares (34.35%)
3	Shares acquired	32,19,113 shares
4	Post-transaction holding	64,97,169 shares (68.09%)
5	Date of transaction	July 2, 2026
6	Mode of transaction	Off Market (Inter se transfer)

Nishu Kansal, Company Secretary & Compliance Officer of Nureca Limited, confirmed the disclosure to BSE Limited and the National Stock Exchange of India Limited. The filings ensured compliance with regulatory requirements regarding the transfer of shares among promoter group members.

Historical Stock Returns for Nureca

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+12.01%	+20.10%	+18.51%	-3.16%	-4.04%	-82.96%

How will the consolidation of 68.09% ownership influence Saurabh Goyal's future strategic decisions regarding Nureca's direction?

Could this increase in promoter stake lead to a delisting offer or a reduction in public float in the future?

What impact will the removal of the transferring family member's stake have on the company's board composition or governance structure?

Financial Performance

The company delivered a significant operational turnaround in FY26, posting an operating profit of ₹8.5 crore compared to an operating loss of ₹7.5 crore in FY25. This turnaround was driven by enhanced operational efficiencies after three consecutive years of losses. However, the company reported a loss for the current quarter (Q4 FY26) due to a fair value loss on investments.

Metric	FY 2025-26	FY 2024-25	Change
Revenue from operations (₹ in million)	1,469.93	1,096.61	34.02%
EBITDA (₹ in million)	82.78	49.00	68.94%
Profit after tax (₹ in million)	20.82	8.46	146.10%

Operational Highlights

Gross merchandise value (GMV) for the year stood at ₹2,029.86 million, an increase of 17.51% from ₹1,730 million in FY25. The EBITDA margin improved to 5.63% in FY26 from 4% in FY25. Net profit margins also improved to 1.47% from 1.07% in the previous year.

Corporate Developments

The Board of Directors has recommended the re-appointment of Mr. Saurabh Goyal as Chairman & Managing Director for a period of three years with effect from September 3, 2026. Additionally, the Board has recommended the appointment of Ms. Smita Goyal as a Whole-time Director for a period of three years with effect from June 01, 2026.

The company’s wholly-owned subsidiary, Nureca Healthcare Private Limited, was dissolved and struck off from the Register of Companies with effect from December 3, 2025.

Historical Stock Returns for Nureca